SCHEMBL4192871

SCHEMBL4192871

COC(=O)c1nn2c(c1OCc1ccccc1)C(=O)N(C)CC2c1cccnc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
CYP3A4 P08684 3/20 0.40
CYP2C9 P11712 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
CYP2C19 P33261 1/20 0.40
USP2 O75604 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
CASP1 P29466 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HTT P42858 1/20 0.38
LMNA P02545 2/20 0.38
POLB P06746 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
APOBEC3A P31941 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4046964 0.85 LMNA (0.39) ALDH1A1USP2MAPTNPSR1HSD17B10
SCHEMBL4200641 0.83 HTT (0.41) ALDH1A1CYP3A4KDM4EGAAMAPK1
SCHEMBL4049772 0.83 RIPK1 (0.37) ALDH1A1KDM4EMAPK1NPSR1LMNA
SCHEMBL4206967 0.83 RIPK1 (0.37) ALDH1A1KDM4EMAPK1NPSR1LMNA
SCHEMBL4203827 0.81 LMNA (0.42) ALDH1A1USP2MAPTHSD17B10LMNA
SCHEMBL18632625 0.81 LMNA (0.41) ALDH1A1USP2MAPTHSD17B10HTT
SCHEMBL4200617 0.81 LMNA (0.41) ALDH1A1GAAUSP2MAPTHSD17B10
SCHEMBL4196402 0.78 ALDH1A1 (0.41) ALDH1A1USP2MAPTHSD17B10HTT
SCHEMBL4207598 0.78 EGFR (0.40) ALDH1A1KDM4EGAAUSP2NPSR1
SCHEMBL4201674 0.78 APP (0.40) ALDH1A1USP2NPSR1HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758585-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-07-22 EP disclosed
US-7476666-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-01-13 US disclosed
US-20080015187-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-17 US disclosed
EP-1758585-A2 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2007-03-07 EP disclosed
WO-2005120516-A2 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015187-A1 Hiv Integrase Inhibitors REV1, ZC3HAV1, PNP ALDH1A1 3490/4885CYP3A4 298/4885CYP2C9 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.